“Ozempic causes vision loss.”

• A retrospective cohort study of ~17,000 patients at Mass Eye and Ear (Hathaway et al., JAMA Ophthalmology, July 2024) found semaglutide-prescribed patients had a markedly higher rate of non-arteritic anterior ischemic optic neuropathy (NAION) — hazard ratio roughly 4 in type 2 diabetes and roughly 7 in overweight/obesity patients. NAION typically causes sudden, permanent, irreversible loss of vision in the affected eye.
• European regulators acted on the signal: after reviewing cohort data and post-marketing reports, the EMA's Pharmacovigilance Risk Assessment Committee concluded in 2025 that NAION is a side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy) with a frequency of 'very rare' (up to 1 in 10,000 people), and required this to be added to the EU product information — a formal regulatory causality judgment, not merely a hypothesis.
• The approved Ozempic prescribing information already carries a warning about diabetic retinopathy complications. In the SUSTAIN-6 cardiovascular outcomes trial (NEJM 2016), retinopathy complications (vitreous hemorrhage, blindness, or need for intravitreal/photocoagulation treatment) occurred in 3.0% of semaglutide patients versus 1.8% on placebo (HR 1.76), so a drug-associated pathway to vision loss is documented in a randomized trial.
• Multiple published case reports and case series describe NAION occurring in patients shortly after starting semaglutide, which contributed to the pharmacovigilance signal.

• The claim as written is unqualified and implies a general or likely effect; the actual regulatory frequency assigned to NAION is 'very rare' — on the order of 1 in 10,000 users or fewer. The overwhelming majority of Ozempic users will never experience vision loss.
• The strongest supporting study was an observational, single-center cohort subject to confounding by indication and referral bias: patients with diabetes, obesity, hypertension and sleep apnea already carry elevated baseline NAION risk, and the comparison groups were not randomized.
• Subsequent larger database and claims-based analyses have produced heterogeneous results, with some finding no statistically significant excess of NAION in semaglutide users; the evidence base is conflicting rather than settled, and absolute event counts in all studies are small.
• The diabetic retinopathy signal in SUSTAIN-6 is widely attributed to rapid improvement in glycemic control in patients with pre-existing retinopathy on insulin — a well-known phenomenon ('early worsening') also seen with insulin and after bariatric surgery — and is generally transient, while sustained glycemic control and weight loss reduce long-term retinopathy progression. On balance, eye outcomes for most diabetic patients are expected to improve, not worsen.
• Regulators did not withdraw or restrict the drug; they added a rare-adverse-event warning, which is a very different public health message from the blanket statement 'Ozempic causes vision loss.'

84/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMA Ophthalmology (Hathaway et al., Mass Eye and Ear / Harvard)journal · 90 · New England Journal of Medicine (SUSTAIN-6, Marso et al.)journal · 96 · European Medicines Agency — Ozempic EPAR and product informationgov · 95 · U.S. FDA, Drugs@FDA (Ozempic/semaglutide, NDA 209637) — approved labeling including diabetic retinopathy warninggov · 95 · PubMed Central (indexed literature on semaglutide and NAION)journal · 80

• Ozempic’s FDA-approved prescribing information warns about diabetic retinopathy complications: in a 2-year trial, diabetic retinopathy complications occurred in 3.0% of Ozempic-treated patients vs 1.8% on placebo, and patients with a history of diabetic retinopathy should be monitored.
• The SUSTAIN-6 cardiovascular outcomes trial published in NEJM found a statistically significant increase in diabetic retinopathy complications with semaglutide vs placebo; severe diabetic retinopathy can threaten vision.
• A 2024 JAMA Ophthalmology retrospective study reported an association between semaglutide prescriptions and nonarteritic anterior ischemic optic neuropathy, a rare optic-nerve condition that can cause sudden vision loss. The study raised a safety signal but did not prove causation.

• The statement is too broad as written: evidence does not show that Ozempic commonly or directly causes vision loss in most users.
• The diabetic-retinopathy signal appears concentrated in patients with pre-existing diabetic retinopathy, poor baseline glucose control, and rapid HbA1c improvement; this pattern is consistent with known early worsening of diabetic retinopathy after rapid glucose lowering, not necessarily a unique toxic effect of Ozempic.
• The JAMA Ophthalmology NAION study was observational and subject to confounding, referral bias, and coding limitations; it found an association, not proof that semaglutide causes the condition.
• Medical guidance generally recommends eye monitoring for higher-risk diabetes patients rather than avoiding semaglutide categorically. Temporary blurred vision or vision changes from shifting blood sugar are not the same as permanent vision loss.

86/100 — the lab’s own confidence in the score above, not a second reading of the claim.

Novo Nordisk / FDA-approved prescribing informationother · 85 · New England Journal of Medicinejournal · 95 · Diabetes, Obesity and Metabolismjournal · 90 · JAMA Ophthalmologyjournal · 92 · American Diabetes Association / Diabetes Carejournal · 94

• A July 2024 observational study published in JAMA Ophthalmology found a significant association between semaglutide (the active ingredient in Ozempic) and an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless vision loss.
• The official FDA prescribing information for Ozempic includes a warning for 'Diabetic Retinopathy Complications.' It notes that rapid improvement in blood glucose control can be associated with a temporary worsening of diabetic retinopathy, which can lead to vision changes or vision loss.

• The JAMA Ophthalmology study was observational; it established a correlation or 'association' between semaglutide and NAION, but the authors explicitly noted it does not prove direct causation.
• NAION is a very rare condition, meaning the absolute risk to patients taking Ozempic remains extremely low.
• Worsening of diabetic retinopathy is a known consequence of rapidly lowering blood sugar levels with any effective diabetes treatment, rather than a direct toxic effect of Ozempic on the eye.
• The blanket claim 'Ozempic causes vision loss' is exaggerated and strips away vital context. It implies a definitive, common, and direct causal link, whereas the evidence points to rare associations (NAION) or secondary complications from rapid glucose reduction.

95/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMA Ophthalmologyjournal · 95 · CNNnews · 85 · Novo Nordisk / FDAother · 95

• Ozempic’s FDA prescribing information reports diabetic-retinopathy complications in 3.0% of Ozempic-treated participants versus 1.8% with placebo over two years; the difference was larger among participants with pre-existing diabetic retinopathy (8.2% versus 5.2%). It advises patients to contact a physician for vision changes. [2]
• A 2025 JAMA Ophthalmology study involving 37.1 million adults with type 2 diabetes found a small increase in the relative incidence of non-arteritic anterior ischemic optic neuropathy (NAION), a rare cause of sudden vision loss, among semaglutide users. [4]
• A 2024 retrospective Danish study reported more than twice the risk of NAION among semaglutide users, although its observational design cannot prove causation. [5]

• The claim is too broad: evidence concerns specific eye complications and a possible association with rare NAION, not established, general vision loss caused by Ozempic in typical users. [2][4][10]
• The FDA evidence shows an increased risk of diabetic-retinopathy complications mainly in people with diabetes and especially those with pre-existing retinopathy; it does not establish that Ozempic generally causes blindness or permanent vision loss. [2]
• A 2025 medical review reported inconsistent study results, with relative NAION risk ranging from nonsignificant to fourfold, low absolute event numbers, and no established causal link because the principal studies were retrospective. [10]
• A review of the literature notes that some studies found no significant increase in NAION or ischemic optic neuropathy among semaglutide users compared with matched controls. [9]

94/100 — the lab’s own confidence in the score above, not a second reading of the claim.

U.S. Food and Drug Administrationgov · 99 · JAMA Ophthalmologyjournal · 97 · International Journal of Retina and Vitreousjournal · 92 · PubMed; review in a medical journaljournal · 94 · PubMed Central; peer-reviewed review articlejournal · 90

• A July 2024 observational study in JAMA Ophthalmology found patients prescribed semaglutide had a substantially higher subsequent rate of NAION (a condition causing sudden, often irreversible vision loss) than matched patients on other drugs.
• Ozempic prescribing information has long warned that rapid glucose lowering can worsen diabetic retinopathy complications, which can include vision loss, especially in patients who already have retinopathy.
• Post-marketing case reports and patient accounts describe sudden vision changes temporally associated with starting semaglutide.

• The JAMA NAION analysis was retrospective and cannot prove causation; people prescribed Ozempic typically have more severe diabetes, obesity, and vascular risk factors that independently raise NAION risk.
• Randomized trials of semaglutide did not show a clear NAION imbalance (the event is rare). Novo Nordisk has stated it sees no causal link in its data.
• Diabetes itself is a major cause of vision loss; absolute NAION risk remains low even in the observational data. Rapid glycemic improvement from any effective therapy can transiently worsen retinopathy.

78/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMA Ophthalmologyjournal · 95 · PubMed/NCBIgov · 92 · Reutersnews · 88 · Novo Nordiskother · 72